Patrick Wenzel

Patrick Wenzel

Auto-generated profile, based on publicly available information

Patrick Wenzel

Department of Internal Medicine II, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
PWPatrick Wenzel
Patrick Wenzel
CMCarolin Mogler
Carolin Mogler
KGKıvanç Görgülü
Kıvanç Görgülü
HAHana Algül
Hana Algül
Pancreatic ductal adenocarcinoma (PC) ranks among the deadliest cancers, with a less than 15% 5-year survival rate. Epidemiological studies project that it will become the second leading cause of cancer-associated mortalities in the following decades. The hallmarks of pancreatic cancer lead to tumor aggressiveness and therapeutic resistance. For this reason, the field has been focusing on multiple dimensions to generate better therapeutic approaches, including new adjuvant, neoadjuvant, and palliative concepts to extend the survival of PC patients. Over the last 2 decades, clinical trials have significantly improved disease prognosis and patient survival. To achieve better outcomes and to deeply understand the therapeutic approaches, molecular tumor boards have become crucial for deeper exploitation of tumor genetics and tumor biology, providing better stratification markers for therapeutic regimens. Using recently developed targeted therapies, such as KRAS inhibitors, the field has gathered momentum and been tooled up with the help of new sequencing technologies. Therefore, researchers and clinicians have geared up for the battle against PC. This review will systematically discuss recent developments in adjuvant, neoadjuvant, and palliative treatment modalities. Moreover, the paradigm-shifting importance of genetic profiling on pancreatic cancer. will be explained through a showcase to frame future directions. Cite this article as: Wenzel P, Mogler C, Görgülü K, Algül H. Pancreatic cancer: current concepts, trends, and future directions. Turk J Gastroenterol. 2025;36(2):69-81.

27 March 2025 in Journal of Hepatology
Verified
Journal Article
Open access
CYChanghoon Yoo
Changhoon Yoo
ASAnna Saborowski
Anna Saborowski
JHJaewon Hyung
Jaewon Hyung
PWPatrick Wenzel
Patrick Wenzel
IKIlwhan Kim
Ilwhan Kim
Arndt VogelArndt Vogel
Arndt Vogel
Liposomal irinotecan (nal-IRI) combined with fluorouracil (5-FU)/leucovorin (LV) as a second-line treatment for biliary tract cancer (BTC) following progression on gemcitabine-based therapy in the Korean NIFTY and German NALIRICC trials yielded conflicting outcomes. This necessitated a comprehensive pooled analysis to evaluate its efficacy and safety. Individual patient data were pooled from the intention-to-treat populations of the NIFTY and NALIRICC trials. The primary endpoint was progression-free survival (PFS). A total of 278 patients were included: 137 in the nal-IRI plus 5-FU/LV group and 141 in the 5-FU/LV group. The nal-IRI plus 5-FU/LV group showed significantly longer median PFS (3.6 months [95% confidence interval [CI], 2.7-4.4] vs 1.8 months (95% CI, 1.5-2.6), hazard ratio [HR) 0.65, p<0.001). Median overall survival was 8.1 months (95% CI, 6.0-8.9) and 6.1 months (95% CI, 5.3-7.5), respectively (HR 0.77, p=0.051). Overall response rates (ORR) was also higher in the nal-IRI plus 5-FU/LV group (17.5% vs 2.8%; p<0.001) than in the 5-FU/LV group. Post-study irinotecan-containing therapy was administered in 4 (2.9%) and 21 (15.3%) patients in the nal-IRI plus 5-FU/LV group and 5-FU/LV group, respectively. Adverse events varied by ethnicity, with gastrointestinal toxicities more common in Germans and neutropenia more prevalent in Koreans; treatment discontinuation without disease progression was 31.3% vs 8.0%, respectively. The addition of nal-IRI to 5-FU/LV significantly improved PFS and ORR, supporting its potential as subsequent-line therapy. Differences in safety profiles underscore the relevance of ethnicity for nal-IRI in patients with BTC. Current standard of care for second-line therapy in patients with advanced biliary tract cancer (BTC) is FOLFOX. This study provides robust evidence supporting the potential role of additional liposomal irinotecan (nal-IRI) to fluorouracil and leucovorin (5-FU/LV) as a subsequent therapy for patients with BTC who have progressed on gemcitabine-based regimens. The findings demonstrate significant improvements in progression-free survival and overall response rates, emphasizing its potential to address the limited treatment options in this patient population. Furthermore, the study underscores the necessity of considering ethnic differences in adverse event profiles to optimize treatment administration and patient outcomes. NCT03524508 and NCT03043547.